Related Experiment Videos
Is the combination between beta-blockers and calcium antagonists appropriate in the management of angina pectoris?
1Laboratoire de Pharmacodynamie Générale et de Pharmacologie, Université Catholique de Louvain, Belgium.
Acta Clinica Belgica
|January 1, 1990
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
[Calcium channel blockers and tissue remodeling in hypertension].
Bulletin et memoires de l'Academie royale de medecine de Belgique·2002
Effects of amlodipine and lacidipine on cardiac remodelling and renin production in salt-loaded stroke-prone hypertensive rats.
British journal of pharmacology·2001
New insights into the therapeutic mechanism of action of calcium channel blockers in salt-dependent hypertension: their interaction with endothelin gene expression.
Journal of cardiovascular pharmacology·2001
Lacidipine prevents endothelial dysfunction in salt-loaded stroke-prone hypertensive rats.
Hypertension (Dallas, Tex. : 1979)·2001
Carvedilol and lacidipine prevent cardiac hypertrophy and endothelin-1 gene overexpression after aortic banding.
Hypertension (Dallas, Tex. : 1979)·1999
Pitfalls in the diagnosis of diffuse large B-cell lymphoma with flow cytometry.
Acta clinica Belgica·2026
Atypical late neurosyphilis presenting as status epilepticus: diagnostic and screening implications.
Acta clinica Belgica·2026
Meta-Analysis: Potassium-Competitive Acid Blockers Versus Proton Pump Inhibitors for Gastroprotection in Patients Receiving Antiplatelet Therapy.
Alimentary pharmacology & therapeutics·2026
Current practices, challenges, and future directions in subcutaneous oncology monoclonal antibody delivery: a qualitative study.
Expert opinion on drug delivery·2026
Ensuring patient rights, safety, and welfare in "compassionate use" of drugs.
Perspectives in clinical research·2026
Pediatric obesity pharmacotherapy: a practical guide for general pediatricians.
Current opinion in pediatrics·2026
Old Drugs, New Targets: Molecular Docking Insights into Repurposing Proton Pump Inhibitors for the TLR4/MD-2, NLRP3, and C5aR1 Axes in Autoimmune Liver Diseases.
Pharmaceuticals (Basel, Switzerland)·2026